المؤلفون: Massari, Francesco, Santoni, Matteo, Takeshita, Hideki, Okada, Yohei, Tapia, Jose Carlos, Basso, Umberto, Maruzzo, Marco, Scagliarini, Sarah, Büttner, Thomas, Fornarini, Giuseppe, Myint, Zin W., Galli, Luca, Souza, Vinicius Carrera, Pichler, Renate, De Giorgi, Ugo, Gandur, Nathalia, Lam, Elaine T., Gilbert, Danielle, Popovic, Lazar, Grande, Enrique, Mammone, Giulia, Berardi, Rossana, Crabb, Simon J., Kemp, Robert, Molina-Cerrillo, Javier, Freitas, Marcelo, Luz, Murilo, Iacovelli, Roberto, Calabrò, Fabio, Tural, Deniz, Atzori, Francesco, Küronya, Zsófia, Chiari, Rita, Campos, Saul, Caffo, Orazio, Fay, André P., Kucharz, Jakub, Zucali, Paolo Andrea, Rinck, José Augusto, Zeppellini, Annalisa, Bastos, Diogo Assed, Aurilio, Gaetano, Mota, Augusto, Trindade, Karine, Ortega, Cinzia, Sade, Juan Pablo, Rizzo, Mimma, Fiala, Ondřej, Vau, Nuno, Giannatempo, Patrizia

الوصف: Background: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Patients and Methods: Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). Cox proportional hazards models were adopted to explore the presence of prognostic factors. Results: In total, 836 patients were included: 544 patients (65%) received pembrolizumab after progression to first-line platinum-based chemotherapy in the metastatic setting (cohort A) and 292 (35%) after recurring within < 12 months since the completion of adjuvant or neoadjuvant chemotherapy (cohort B). The median follow-up time was 15.3 months. The median OS and the ORR were 10.5 months and 31% in the overall study population, 9.1 months and 29% in cohort A and 14.6 months and 37% in cohort B. At multivariate analysis, ECOG-PS ≥ 2, bone metastases, liver metastases and pembrolizumab setting (cohort A vs B) proved to be significantly associated with worst OS and PFS. Stratified by the presence of 0, 1–2 or 3–4 prognostic factors, the median OS was 29.4, 12.5 and 4.1 months (p < 0.001), while the median PFS was 12.2, 6.4 and 2.8 months, respectively (p < 0.001). Conclusions: Our study confirms that pembrolizumab is effective in the advanced UC real-world context, showing outcome differences between patients recurred or progressed after platinum-based chemotherapy.

وصف الملف: text

العلاقة: https://eprints.soton.ac.uk/489845/1/s00262-024-03682-w.pdfTest; Massari, Francesco, Santoni, Matteo and Takeshita, Hideki , et al. (2024) Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. Cancer immunology, immunotherapy : CII, 73 (6), [106]. (doi:10.1007/s00262-024-03682-w ).

الإتاحة: https://doi.org/10.1007/s00262-024-03682-wTest
https://eprints.soton.ac.uk/489845Test/
https://eprints.soton.ac.uk/489845/1/s00262-024-03682-w.pdfTest

المؤلفون: Santoni, Matteo, Buti, Sebastiano, Myint, Zin W., Maruzzo, Marco, Iacovelli, Roberto, Pichler, Martin, Kopecky, Jindrich, Kucharz, Jakub, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Kopp, Ray Manneh, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Massari, Francesco, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Sunela, Kaisa, Bassanelli, Maria, Ortega, Cinzia, Grillone, Francesco, Landmesser, Johannes, Milella, Michele, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Santini, Daniele, Vau, Nuno, Morelli, Franco, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Soares, Andrey, Bisonni, Renato, Bimbatti, Davide, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Battelli, Nicola, Bracarda, Sergio, Porta, Camillo

المساهمون: Santoni, Matteo, Buti, Sebastiano, Myint, Zin W., Maruzzo, Marco, Iacovelli, Roberto, Pichler, Martin, Kopecky, Jindrich, Kucharz, Jakub, Rizzo, Mimma, Galli, Luca, Büttner, Thoma, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Kopp, Ray Manneh, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Toma, Massari, Francesco, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristoteli, Caffo, Orazio, Procopio, Giuseppe, Sunela, Kaisa, Bassanelli, Maria, Ortega, Cinzia, Grillone, Francesco, Landmesser, Johanne, Milella, Michele, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Santini, Daniele, Vau, Nuno, Morelli, Franco, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Soares, Andrey, Bisonni, Renato, Bimbatti, Davide, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Battelli, Nicola, Bracarda, Sergio, Porta, Camillo

مصطلحات موضوعية: ARON-1 study, Immune-oncology combination, Immunotherapy, Intermediate-risk International Metastatic Renal Cell Carcinoma Database Consortium criteria, NCT05287464, Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium criteria, Renal cell carcinoma, Survival

الوصف: Background: Renal c carcinoma (RCC) is one of the most common urinary cancers worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a single agent, in doublets, or in combination with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs), has rapidly become a cornerstone of the RCC therapeutic scenario, but no head -to -head comparisons have been made. In this setting, real -world evidence emerges as a cornerstone to guide clinical decisions. Objective: The objective of this retrospective study was to assess the outcome of patients treated with first -line immune combinations or immune oncology (IO)-TKIs for advanced RCC. Design, setting, and participants: Data from 930 patients, 654 intermediate risk and 276 poor risk, were collected retrospectively from 58 centers in 20 countries. Special data such as sarcomatoid differentiation, body mass index, prior nephrectomy, and metastatic localization, in addition to biochemical data such as hemoglobin, platelets, calcium, lactate dehydrogenase, neutrophils, and radiological response by investigator's criteria, were collected. Outcome measurements and statistical analysis: Overall survival (OS) and progressionfree survival (PFS) were estimated using the Kaplan -Meier method. The median follow-up was calculated by the inverse Kaplan -Meier method. Results and limitations: The median follow-up time was 18.7 mo. In the 654 intermediate -risk patients, the median OS and PFS were significantly longer in patients with the intermediate than in those with the poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria (38.9 vs 17.3 mo, 95% confidence interval [CI] p < 0.001, and 17.3 vs 11.6 mo, 95% CI p < 0.001, respectively). In the intermediate -risk subgroup, the OS was 55.7 mo (95% CI 31.4-55.7) and 40.2 mo (95% CI 29.6-51.6) in patients treated with IO + TKI and IO + IO combinations, respectively (p = 0.047). PFS was 30.7 mo (95% CI 16.5-55.7) and 13.2 mo (95% CI 29.6-51.6) ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37481365; info:eu-repo/semantics/altIdentifier/wos/WOS:001171176000001; volume:7; issue:1; firstpage:102; lastpage:111; numberofpages:10; journal:EUROPEAN UROLOGY ONCOLOGY; https://hdl.handle.net/11573/1705093Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85184074251

الإتاحة: https://doi.org/10.1016/j.euo.2023.07.003Test
https://hdl.handle.net/11573/1705093Test

المؤلفون: Santoni, Matteo, Massari, Francesco, Matrana, Marc R, Basso, Umberto, De Giorgi, Ugo, Aurilio, Gaetano, Buti, Sebastiano, Incorvaia, Lorena, Rizzo, Mimma, Martignetti, Angelo, Maslov, Diana, Tawagi, Karine, Philon, Ernest, Blake, Zoe, Porta, Camillo, Battelli, Nicola

المساهمون: Santoni, Matteo, Massari, Francesco, Matrana, Marc R, Basso, Umberto, De Giorgi, Ugo, Aurilio, Gaetano, Buti, Sebastiano, Incorvaia, Lorena, Rizzo, Mimma, Martignetti, Angelo, Maslov, Diana, Tawagi, Karine, Philon, Ernest, Blake, Zoe, Porta, Camillo, Battelli, Nicola

مصطلحات موضوعية: Concomitant medications, Immunotherapy, Nivolumab, Renal cell carcinoma, Statin, Survival, Tumour response, Child, Preschool, Humans, Progression-Free Survival, Retrospective Studies, Treatment Outcome, Carcinoma, Renal Cell, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kidney Neoplasms

الوصف: Background: Statins are widely used in an ageing population, including subjects with solid malignancies. However, no conclusive evidence is currently available on their potential influence on patients' outcome. We aimed to assess whether statin exposure affects the survival of patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Patients and methods: Medical records of patients with documented mRCC treated with second- or third-line nivolumab were reviewed at ten institutions from Italy, Spain and the USA. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit. Univariate and multivariate analyses were used to explore the association of variables of interest with survival.Results: A total of 219 patients with mRCC receiving nivolumab between January 2016 and September 2021 were eligible for inclusion in this study; 59 (27%) were statin users. The median OS (34.4 versus 18.6 months, p = 0.017) and PFS (11.7 versus 4.6 months, p = 0.013) resulted apparently longer in statin users. Stratified by age, longer median OS and PFS were associated with statin exposure in both patients aged >= 70 y (median OS: 21.4 versus 10.1 months, p = 0.047; median PFS: 16.4 versus 4.6 months, p = 0.022) and <70 y (median OS: 34.4 versus 21.4 months, p = 0.043; median PFS: 10.3 versus 4.6 months, p = 0.042). Overall clinical benefit resulted higher in statin users than non-users (71% versus 54%, p = 0.030).Conclusions: Our study suggests a prognostic impact of statin use in patients receiving nivolumab for mRCC. (C) 2022 Elsevier Ltd. All rights reserved.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35780525; info:eu-repo/semantics/altIdentifier/wos/WOS:000833528400016; volume:172; firstpage:191; lastpage:198; numberofpages:8; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/10447/570885Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85132991221

الإتاحة: https://doi.org/10.1016/j.ejca.2022.04.035Test
http://hdl.handle.net/10447/570885Test

المؤلفون: Pesapane, Filippo, Rotili, Anna, Raimondi, Sara, Aurilio, Gaetano, Lazzeroni, Matteo, Nicosia, Luca, Latronico, Antuono, Pizzamiglio, Maria, Cassano, Enrico, Gandini, Sara

المصدر: European Journal of Radiology ; volume 172, page 111321 ; ISSN 0720-048X

مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging, General Medicine

الإتاحة: https://doi.org/10.1016/j.ejrad.2024.111321Test
https://api.elsevier.com/content/article/PII:S0720048X24000378?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0720048X24000378?httpAccept=text/plainTest

المؤلفون: Maiorano, Brigida Anna, Di Maio, Massimo, Cerbone, Linda, Maiello, Evaristo, Procopio, Giuseppe, Roviello, Giandomenico, Accettura, Caterina, Aieta, Michele, Alberti, Martina, Aliprandi, Marta, Altavilla, Amelia, Antonuzzo, Lorenzo, Artemi, Adele, Arundine, Dario, Astore, Serena, Attademo, Laura, Atzori, Francesco, Aurilio, Gaetano, Azzariti, Amalia, Baciarello, Giulia, Baier, Susanne, Baldazzi, Valentina, Banna, Giuseppe L, Barile, Carmen, Barra, Salvina, Barraco, Chiara, Basile, Debora, Bassanelli, Maria, Basso, Umberto, Bauckneht, Matteo, Bearz, Alessandra, Bellia, Salvatore R, Benedetti, Benedetta, Berardi, Rossana, Bergamini, Marco, Bersanelli, Melissa, Bertoni, Maria, Bianchi, Emanuela, Biasini, Claudia, Bidin, Livia, Bimbatti, Davide, Bleve, Sara, Boccardo, Francesco, Bolzacchini, Elena, Bonato, Adele, Bonomi, Lucia, Bordonaro, Sebastiano, Borghesi, Marco, Bortolus, Roberto, Bortot, Lucia

المصدر: JAMA Network Open ; volume 7, issue 3, page e241215 ; ISSN 2574-3805

الوصف: Importance Immune checkpoint inhibitors (ICIs) have broadened the metastatic urothelial carcinoma (mUC) therapeutic scenario. The association of programmed death ligand 1 (PD-L1) with response and survival in patients treated with ICIs is still controversial. Objectives To evaluate the association of PD-L1 with response rate and overall survival among patients with mUC treated with ICIs. Data Sources PubMed, Embase, American Society of Clinical Oncology and European Society for Medical Oncology Meeting Libraries, and Web of Science were searched up to December 10, 2023. Study Selection Two authors independently screened the studies. Included studies were randomized and nonrandomized clinical trials enrolling patients with mUC receiving ICIs with available overall survival (OS), progression-free survival (PFS), or overall response rate (ORR) data, separated between patients with PD-L1–positive and –negative tumors. Data Extraction and Synthesis The Preferred Reporting Items for Systematic Reviews and Meta-analyses ( PRISMA ) reporting guideline was followed. Two reviewers independently extracted data. Fixed- or random-effects models were used depending on the heterogeneity among the studies. Main Outcomes and Measures Primary outcomes were odds ratios (ORs) for ORR and hazard ratios (HRs) for OS, comparing patients with PD-L1–positive tumors and patients with PD-L1–negative tumors. Secondary outcomes were the PFS HR between patients with PD-L1–positive and –negative tumors and OS HR between ICI arms and non-ICI arms of only randomized clinical trials. Results A total of 14 studies were selected, comprising 5271 patients treated with ICIs (2625 patients had PD-L1–positive tumors). The ORR was 13.8% to 78.6% in patients with PD-L1–positive tumors and 5.1% to 63.2% in patients with PD-L1–negative tumors, with an association between PD-L1 status and ORR favoring patients with PD-L1–positive tumors (OR, 1.94; 95% CI, 1.47-2.56; P < .001). Median OS ranged from 8.4 to 24.1 months in patients with ...

الإتاحة: https://doi.org/10.1001/jamanetworkopen.2024.1215Test
https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2815767/maiorano_2024_oi_240074_1708699219.17392.pdfTest

المؤلفون: Dieckmann, Klaus-Peter, Pokrivcak, Tomas, Geczi, Lajos, Niehaus, David, Dralle-Filiz, Inken, Matthies, Cord, Dienes, Tamas, Zschäbitz, Stefanie, Paffenholz, Pia, Gschliesser, Tanja, Pichler, Renate, Mego, Michal, Bader, Pia, Zengerling, Friedemann, Heinzelbecker, Julia, Krausewitz, Philipp, Krege, Susanne, Aurilio, Gaetano, Aksoy, Cem, Hentrich, Marcus, Seidel, Christoph, Törzsök, Péter, Nestler, Tim, Majewski, Matthaeus, Hiester, Andreas, Buchler, Tomas, Vallet, Sonia, Studentova, Hana, Schönburg, Sandra, Niedersüß-Beke, Dora, Ring, Julia, Trenti, Emanuela, Heidenreich, Axel, Wülfing, Christian, Isbarn, Hendrik, Pichlmeier, Uwe, Pichler, Martin

المصدر: Therapeutic Advances in Medical Oncology ; volume 14, page 175883592210868 ; ISSN 1758-8359 1758-8359

مصطلحات موضوعية: Oncology

الوصف: Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population. Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6–89) months. Primary end points were relapse-free and overall survival evaluated after 5 years. We also looked at associations of relapse with clinico-pathological factors using stratified Kaplan–Meier methods and Cox regression models. Treatment modality and outcome of recurrences were analyzed descriptively. Results: The 5-year relapse-free survival rate was 96.2%. Thirteen patients (3.1%; 95% confidence interval, 1.65–5.04%) relapsed after a median time of 13 months, of which 10 were salvaged (77%). Relapses were mostly confined to retroperitoneal nodes. Three patients succumbed, two to disease progression and one to toxicity of chemotherapy. Pathological stage >pT2 was significantly associated with relapse rate. Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.

الإتاحة: https://doi.org/10.1177/17588359221086813Test

المؤلفون: Buti, Sebastiano, Bersanelli, Melissa, Massari, Francesco, De Giorgi, Ugo, Caffo, Orazio, Aurilio, Gaetano, Basso, Umberto, Carteni, Giacomo, Caserta, Claudia, Galli, Luca, Boccardo, Francesco, Procopio, Giuseppe, Facchini, Gaetano, Fornarini, Giuseppe, Berruti, Alfredo, Fea, Elena, Naglieri, Emanuele, Petrelli, Fausto, Iacovelli, Roberto, Porta, Camillo, Mosca, Alessandra

المساهمون: Buti, Sebastiano, Bersanelli, Melissa, Massari, Francesco, De Giorgi, Ugo, Caffo, Orazio, Aurilio, Gaetano, Basso, Umberto, Carteni, Giacomo, Caserta, Claudia, Galli, Luca, Boccardo, Francesco, Procopio, Giuseppe, Facchini, Gaetano, Fornarini, Giuseppe, Berruti, Alfredo, Fea, Elena, Naglieri, Emanuele, Petrelli, Fausto, Iacovelli, Roberto, Porta, Camillo, Mosca, Alessandra

مصطلحات موضوعية: Kidney cancer, Non-clear cell, Pazopanib, Renal-cell carcinoma, Tyrosine kinase inhibitor, Variant histology

الوصف: BACKGROUNDNon-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal phase III trials excluded patients with nccRCC, which constitute about 30% of metastatic RCC cases.AIMTo provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.METHODSThe present study is a multicenter retrospective observational analysis aiming to assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.RESULTSOverall, 48 patients were included. At the median follow-up of 40.6 mo, the objective response rate was 27.1%, the disease control rate was 83.3%, and the median progression-free survival and overall survival were 12.3 (95% confidence interval [CI]: 3.6-20.9) and 27.7 (95%CI: 18.2-37.1) mo, respectively. Grade 3 adverse events occurred in 20% of patients, and no grade 4 or 5 toxicities were found.CONCLUSIONPazopanib should be considered as a good first-line option for metastatic RCC with variant histology.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34909398; info:eu-repo/semantics/altIdentifier/wos/WOS:000727715300006; volume:12; issue:11; firstpage:1037-1046; lastpage:1046; journal:WORLD JOURNAL OF CLINICAL ONCOLOGY; http://hdl.handle.net/11379/550797Test

الإتاحة: https://doi.org/10.5306/wjco.v12.i11.1037Test
http://hdl.handle.net/11379/550797Test

المؤلفون: Santoni, Matteo, Massari, Francesco, Myint, Zin W, Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R, Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Merler, Sara, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M, Montironi, Rodolfo, Battelli, Nicola, Porta, Camillo

المساهمون: Santoni, Matteo, Massari, Francesco, Myint, Zin W, Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Rizzo, Mimma, Galli, Luca, Büttner, Thoma, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R, Pichler, Renate, Cattrini, Carlo, Büchler, Toma, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristoteli, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Merler, Sara, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M, Montironi, Rodolfo, Battelli, Nicola, Porta, Camillo

مصطلحات موضوعية: Renal Cell Carcinoma, Immunotherapy, Immuno-oncology Combinations

الوصف: Background: Immuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC). Objective: The ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients. Patients and methods: Patients aged ≥ 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB). Results: A total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p=0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p 

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______3658::4629f19f03a0e2b924f10c7b80f90fe7Test
https://hdl.handle.net/10447/598393Test

المؤلفون: Seidel, Christoph, Daugaard, Gedske, Nestler, Tim, Tryakin, Alexey, Fedyanin, Mikhail, Fankhauser, Christian Daniel, Hermanns, Thomas, Aparicio, Jorge, Heinzelbecker, Julia, Paffenholz, Pia, Heidenreich, Axel, De Giorgi, Ugo, Cathomas, Richard, Lorch, Anja, Fingerhut, Anna, Gayer, Fabian, Bremmer, Felix, Giannatempo, Patrizia, Necchi, Andrea, Raggi, Daniele, Aurilio, Gaetano, Casadei, Chiara, Hentrich, Marcus, Tran, Ben, Dieckmann, Klaus-Peter, Brito, Margarido, Ruf, Christian, Mazzocca, Alessandro, Vincenzi, Bruno, Stahl, Olof, Bokemeyer, Carsten, Oing, Christoph

المصدر: http://lobid.org/resources/99370672102306441Test#!, 39(9):3407-3414.

مصطلحات موضوعية: Adolescent [MeSH], Lactate dehydrogenase, Seminoma, Aged [MeSH], Prognostic markers, Adult [MeSH], Testicular Neoplasms/mortality [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Upper limit of normal, Original Article, L-Lactate Dehydrogenase/blood [MeSH], Neoplasm Staging [MeSH], Survival Rate [MeSH], Male [MeSH], Seminoma/mortality [MeSH], Prognosis [MeSH], Testicular Neoplasms/blood [MeSH], Young Adult [MeSH], Seminoma/pathology [MeSH], Testicular Neoplasms/pathology [MeSH], Seminoma/blood [MeSH]

الوصف: Purpose!#!The prognostic significance of lactate dehydrogenase (LDH) in patients with metastatic seminoma is not defined. We investigated the prognostic impact of LDH levels prior to first-line systemic treatment and other clinical characteristics in this subset of patients.!##!Methods!#!Files from two registry studies and one single-institution database were analyzed retrospectively. Uni- and multivariate analyses were conducted to identify patient characteristics associated with recurrence free survival (RFS), overall survival (OS), and complete response rate (CRR).!##!Results!#!The dataset included 351 metastatic seminoma patients with a median follow-up of 5.36 years. Five-year RFS, OS and CRR were 82%, 89% and 52%, respectively. Explorative analysis revealed a cut-off LDH level of < 2.5 upper limit of normal (ULN) (n = 228) vs. ≥ 2.5 ULN (n = 123) to be associated with a significant difference concerning OS associated with 5-years OS rates of 93% vs. 83% (p = 0.001) which was confirmed in multivariate analysis (HR 2.87; p = 0.004). Furthermore, the cut-off LDH < 2.5 ULN vs. ≥ 2.5 ULN correlated with RFS and CRR associated with a 5-years RFS rate and CRR of 76% vs. 86% (p = 0.012) and 32% vs. 59% (p ≤ 0.001), respectively.!##!Conclusions!#!LDH levels correlate with treatment response and survival in metastatic seminoma patients and should be considered for their prognostic stratification.

العلاقة: https://repository.publisso.de/resource/frl:6447737Test; https://doi.org/10.1007/s00345-021-03635-3Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510898Test/

الإتاحة: https://doi.org/10.1007/s00345-021-03635-3Test
https://repository.publisso.de/resource/frl:6447737Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510898Test/

المؤلفون: Santoni, Matteo, Massari, Francesco, Bracarda, Sergio, Procopio, Giuseppe, Milella, Michele, De Giorgi, Ugo, Basso, Umberto, Aurilio, Gaetano, Incorvaia, Lorena, Martignetti, Angelo, Rizzo, Mimma, Cartenì, Giacomo, Grande, Enrique, Matrana, Marc R, Crabb, Simon J, Vau, Nuno, Sorgentoni, Giulia, Cimadamore, Alessia, Montironi, Rodolfo, Battelli, Nicola

الوصف: We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, p < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, p = 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, p = 0.029) and OS (39.4 months vs. 11.5 months, p = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.

وصف الملف: text

العلاقة: https://eprints.soton.ac.uk/447026/1/diagnostics_1067059_revised_AC_MS_Jan15.docxTest; Santoni, Matteo, Massari, Francesco, Bracarda, Sergio, Procopio, Giuseppe, Milella, Michele, De Giorgi, Ugo, Basso, Umberto, Aurilio, Gaetano, Incorvaia, Lorena, Martignetti, Angelo, Rizzo, Mimma, Cartenì, Giacomo, Grande, Enrique, Matrana, Marc R, Crabb, Simon J, Vau, Nuno, Sorgentoni, Giulia, Cimadamore, Alessia, Montironi, Rodolfo and Battelli, Nicola (2021) Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? Diagnostics, 11 (1), [138]. (doi:10.3390/diagnostics11010138 ).

الإتاحة: https://eprints.soton.ac.uk/447026Test/
https://eprints.soton.ac.uk/447026/1/diagnostics_1067059_revised_AC_MS_Jan15.docxTest